Camurus AB: Camurus' Interim Report Second Quarter 2025

"Successful second quarter for Camurus"

Summary second quarter 2025

April - June

• Total revenues grew 52% (65% at CER¹) to SEK 676 (445) million
• Sales of Buvidal^® increased 17% (26% at CER¹) to SEK 470 (400) million
• Brixadi^® royalties increased 100% (131% at CER¹) to SEK 89 (45) million
• Profit before tax increased 195% to SEK 307 (104) million
• The cash position at the end of the quarter was SEK 3.3 (2.6) billion
• Financial outlook for 2025 maintained
• Camurus and Eli Lilly and Company (Lilly) entered a collaboration and license agreement for long-acting FluidCrystal^® incretins, which generated an initial license revenue of USD 12 million
• The European Commission granted marketing authorization approval for Oczyesa^® for the treatment of acromegaly
• Positive Phase 2b results obtained from the POSITANO study of CAM2029 in patients with polycystic liver disease

January - June

• Total revenues grew 48% to SEK 1,234 (835) million
• Sales of Buvidal increased 25% (28% at CER¹) to SEK 954 (764) million
• Brixadi royalties increased 131% to SEK 163 (71) million
• Profit before tax increased 179% to SEK 561 (201) million

Financial summary second quarter 2025

• Total revenue SEK 676 (445) million
  - whereof product sales SEK 470 (400) million, and royalties SEK 89 (45) million
• OPEX SEK 343 (331) million
• Operating result SEK 292 (83) million
• Profit before tax SEK 307 (104) million
• Result for the period SEK 245 (74) million
• Earnings per share, after dilution, of SEK 4.08 (1.25)

• Cash position SEK 3,347 (2,567) billion

1) At constant exchange rate

Fredrik Tiberg, President and CEO:
"Camurus had a successful second quarter with strong financial results and progress in our development portfolio. Total revenues increased by 52 percent to a record turnover of SEK 676 million, and operating profit amounted to SEK 292 million. Oczyesa^® (CAM2029) received a positive CHMP opinion, which was followed by an approval in the EU for the treatment of acromegaly. Positive results were obtained from the POSITANO study of CAM2029 in patients with polycystic liver disease. Furthermore, we entered into a collaboration and license agreement with Lilly for the development and commercialization of long-acting incretins based on our FluidCrystal^® technology platform."

Webcast
Financial analysts, investors and media are invited to attend a webcast and presentation of the second quarter results at 2.00 pm CET.

Access the webcast using this link: https://camurus.events.inderes.com/q2-report-2025

To participate in the presentation and ask questions, please register using the link below. After registering, please use the provided phone number and conference ID to dial in: https://events.inderes.com/camurus/q2-report-2025/dial-in

For more information:
Fredrik Tiberg, President and CEO
Tel. [phone]
[e-mail]

Fredrik Joabsson, Chief Business Development Officer
Tel. [phone]
[e-mail]

About Camurus
Camurus is an international, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for improving the lives of patients with severe and chronic diseases. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal^® technology and its extensive R&D expertise. The R&D pipeline includes products for the treatment of dependence, pain, cancer, and endocrine diseases. Camurus has operations across Europe, the US, and Australia, with headquarters in Lund Sweden. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com and LinkedIn.

This information is information that Camurus AB is obliged to make public pursuant to the EU Market Abuse Regulation and to the Securities Markets Act. The information was submitted for publication, through the agency of the chief executive officer, at 07.00 am CET on 17 July, 2025.